INVITRO EVALUATION STUDIES OF CROSSLINKED CHITOSAN MICROSPHERES CONTAINING RABEPRAZOLE SODIUM

For many decades treatment of an acute disease or a chronic illness has been mostly accomplished by delivery of drugs to patients using various pharmaceutical dosage forms including tablets, capsules, pills, suppositories, creams, ointment, liquids, aerosols and injectables as drug delivery systems are the primary pharmaceutical products commonly seen in the market.  In the past two and a half decades several advancements has been made in the pharmaceutical products. They have resulted in the development of new techniques for drug delivery¹. These techniques are capable of controlling the rate of drug delivery, sustaining the duration of therapeutic activity and targeting the delivery of drug. A series of three different trial formulation of Rabeprazole Sodium, Microsphere using Chitosan an aminopolysaccharide, so as to optimize the sustained conditions.  In the case of microsphere, the initial formulation was done with 0.5% Chitosan solution and drug. Then the concentration of chitosan had been increased to 1.5%. It showed that the percentage release was maximum 65.2% for the chitosan microsphere in the formulation F3, when compared with other formulation of microsphere containing Rabeprazole sodium, the 1.5% of chitosan showed better release than the other formulations.